Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage

被引:51
|
作者
Kuramatsu, Joji B. [1 ]
Sembill, Jochen A. [1 ]
Huttner, Hagen B. [1 ]
机构
[1] Univ Hosp Erlangen, Dept Neurol, Schwabachanlage 6, D-91054 Erlangen, Germany
来源
CRITICAL CARE | 2019年 / 23卷 / 1期
关键词
Intracerebral hemorrhage; Anticoagulation reversal; Tranexamic acid; Ciraparantag; Desmopressin; PROTHROMBIN COMPLEX CONCENTRATE; VITAMIN-K ANTAGONIST; ACTIVATED FACTOR-VII; FRESH-FROZEN PLASMA; INTRACRANIAL HEMORRHAGE; ANTIPLATELET THERAPY; TRANEXAMIC ACID; OPEN-LABEL; STROKE; DABIGATRAN;
D O I
10.1186/s13054-019-2492-8
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
In light of an aging population with increased cardiovascular comorbidity, the use of oral anticoagulation (OAC) is steadily expanding. A variety of pharmacological alternatives to vitamin K antagonists (VKA) have emerged over recent years (direct oral anticoagulants, DOAC, i.e., dabigatran, rivaroxaban, apixaban, and edoxaban) which show a reduced risk for the occurrence of intracerebral hemorrhage (ICH). Yet, in the event of ICH under OAC (OAC-ICH), hematoma characteristics are similarly severe and clinical outcomes likewise substantially limited in both patients with VKA- and DOAC-ICH, which is why optimal acute hemostatic treatment in all OAC-ICH needs to be guaranteed. Currently, International Guidelines for the hemostatic management of patients with OAC-ICH are updated as several relevant large-sized observational studies and recent trials have established treatment approaches for both VKA- and DOAC-ICH. While the management of VKA-ICH is mainly based on the immediate reversal of elevated levels of international normalized ratio using prothrombin complex concentrates, hemostatic management of DOAC-associated ICH is challenging requiring specific antidotes, notably idarucizumab and andexanet alfa. This review will provide an overview of the latest studies and trials on hemostatic reversal agents and timing and summarizes the effects on hemorrhage progression and clinical outcomes in patients with OAC-ICH.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage
    Joji B. Kuramatsu
    Jochen A. Sembill
    Hagen B. Huttner
    [J]. Critical Care, 23
  • [2] Contemporary Reversal of Oral Anticoagulation in Intracerebral Hemorrhage
    Bower, Matthew M.
    Sweidan, Alexander J.
    Shafie, Mohammad
    Atallah, Steven
    Groysman, Leonid I.
    Yu, Wengui
    [J]. STROKE, 2019, 50 (02) : 529 - 536
  • [3] Practical management for urgent reversal of oral anticoagulation in patients with acute intracerebral haemorrhage
    Imberti, Davide
    [J]. REVIEWS IN HEALTH CARE, 2011, 2 : 93 - 98
  • [4] Intracerebral Hemorrhage in Patients Receiving Oral Anticoagulation Therapy
    da Silva, Ivan Rocha Ferreira
    Provencio, J. Javier
    [J]. JOURNAL OF INTENSIVE CARE MEDICINE, 2015, 30 (02) : 63 - 78
  • [5] EMERGENCY REVERSAL OF ANTICOAGULATION AFTER INTRACEREBRAL HEMORRHAGE
    FREDRIKSSON, K
    NORRVING, B
    STROMBLAD, LG
    [J]. STROKE, 1992, 23 (07) : 972 - 977
  • [6] Oral Anticoagulation after intracerebral Hemorrhage
    不详
    [J]. KARDIOLOGE, 2019, 13 (03): : 121 - 121
  • [7] Intracerebral Hemorrhage under oral Anticoagulation
    Beynon, C.
    Unterberg, A. W.
    [J]. MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2017, 112 (05) : 475 - 486
  • [8] Oral anticoagulation after intracerebral hemorrhage
    Biffi A
    Kuramatsu JB
    Leasure
    [J]. 中华物理医学与康复杂志, 2018, 40 (03) : 190 - 190
  • [9] Reversal of oral anticoagulation in intracranial hemorrhage
    Bosel, J.
    Steiner, T.
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (47) : 2366 - 2369
  • [10] Outcomes after Reversal of Anticoagulation after Intracerebral Hemorrhage
    Hernandez, M.
    Chamorro, M.
    Elfman, J.
    Webb, A.
    Plamootil, C.
    Ganti, L.
    Banerjee, P.
    [J]. ANNALS OF EMERGENCY MEDICINE, 2020, 76 (04) : S84 - S85